{"id":56710,"date":"2026-04-07T13:48:07","date_gmt":"2026-04-07T13:48:07","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/56710\/"},"modified":"2026-04-07T13:48:07","modified_gmt":"2026-04-07T13:48:07","slug":"breakthrough-in-weight-loss-novo-nordisks-high-dose-wegovy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/56710\/","title":{"rendered":"Breakthrough in Weight Loss: Novo Nordisk&#8217;s High-Dose Wegovy"},"content":{"rendered":"<p>&#13;<\/p>\n<p>Novo Nordisk has announced the U.S. release of a higher-dose version of their weight-loss drug, Wegovy. The new 7.2-mg dose, dubbed Wegovy HD, received approval last month via the FDA Commissioner&#8217;s National Priority Review Voucher program.<\/p>\n<p>Until now, the highest approved dose for Wegovy was 2.4 mg, highlighting this as a significant development for the drug&#8217;s availability. The new higher-dose option is accessible through U.S. pharmacies, NovoCare Pharmacy, and select telehealth providers.<\/p>\n<p>For cash-paying adults, Wegovy HD will cost $399 monthly, but those with commercial insurance might pay as little as $25 monthly using Novo&#8217;s savings offer. Furthermore, Novo plans to introduce a discounted subscription plan in response to competition from Eli Lilly in the obesity-drug market.<\/p>\n<p>&#13;<\/p>\n<p>(With inputs from agencies.)<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; Novo Nordisk has announced the U.S. release of a higher-dose version of their weight-loss drug, Wegovy. The&hellip;\n","protected":false},"author":2,"featured_media":56693,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[276,325,272,7979,323,360,31402,1910,24895,280],"class_list":["post-56710","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly","tag-fda","tag-novo-nordisk","tag-obesity-drug","tag-prescription","tag-telehealth","tag-u-s-pharmacies","tag-wegovy","tag-wegovy-hd","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116363742741060890","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/56710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=56710"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/56710\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/56693"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=56710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=56710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=56710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}